Praxis Precision Medicines, Inc. (PRAX) SEC Filings & Earnings Calls

Clinical trial failure risk

“In June 2026, we announced that the primary endpoint was not met in our POWER1 study, a double-blind, placebo-controlled, 12-week study in FOS. We paused enrollment in POWER2, our third efficacy study, to reassess the vormatrigine program and determine potential modifications.” · word for word

Regulatory approval risk

“The FDA notified us that it had extended by three months the review period for our NDA for relutrigine, setting an updated PDUFA action date of December 27, 2026.” · word for word

Capital needs risk

“We will need substantial capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources.” · word for word

Regulatory approval risk remains; PDUFA dates are in the future.

“PDUFA date of January 29, 2027 for ulixacaltamide; December 27, 2026 for relutrigine.”

Regulatory delay for relutrigine NDA, though no safety or manufacturing concerns cited.

“extension follows the Company's submission of additional sensitivity analyses... FDA has deemed a 'major amendment'”

Clinical trial failure for vormatrigine, a key pipeline asset, increasing R&D risk.

“did not meet its primary success measure”

No revenue from product sales

“We have not generated any revenue from the sale of products since inception and our ability to generate revenue from the sale of products in the future will be dependent on regulatory approval of our product candidates.” · word for word

Significant operating losses and accumulated deficit

“We have incurred recurring operating losses since inception, including a net loss of $92.6 million for the three months ended March 31, 2026. As of March 31, 2026, we had an accumulated deficit of $1.2 billion.” · word for word

Need for substantial additional capital

“We will need substantial capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other str” · word for word

Regulatory approval uncertainty

“We may never obtain regulatory approval for any of our product candidates.” · word for word

Clinical trial risks

“If the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and” · word for word

Regulatory risk: NDAs accepted but approval not guaranteed; PDUFA dates are targets.

“PDUFA target action date of January 29, 2027; PDUFA target action date of September 27, 2026”

Clinical trial risk: POWER1, EMERALD, and other readouts pending; negative results could impact pipeline value.

“Topline results from the POWER1 study of vormatrigine in focal onset seizures expected in Q2 2026; EMERALD topline results expected in Q4 2026”

Commercial execution risk: Company has no prior commercial experience; launch readiness is unproven.

“Commercial preparations and pre-launch activities continue to accelerate” · word for word

CNS drug development failure risk

“CNS programs fail at disproportionately high rates relative to other areas of drug development, and the path from genetic insight to approved therapy requires years of sustained scientific, clinical and regulatory rigor under conditions of deep uncertainty.” · word for word

Binary clinical outcome risk

“CNS drug development involves long timelines, binary clinical outcomes and regulatory decisions that can materially shift company value in either direction, often in ways that are outside of management's direct control.” · word for word

Stockholder say-on-pay support decline

“At our 2025 Annual Meeting of Stockholders, approximately 61% of the votes cast supported our say-on-pay proposal. However, in the prior year, our stockholders exhibited stronger support for our executive compensation proposals, with an approval rate of 71% for 2024.” · word for word

Clinical trial risk remains for broader population

“Small sample size (9 patients); results may not generalize to larger population.”

Clinical failure risk

“The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials.” · word for word

Funding risk

“We may need additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product discovery and development programs or commercialization efforts.” · word for word

Preliminary and unaudited financial data subject to adjustment; no audit opinion provided.

“The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates... subject to completion of the Company’s financial closing procedures.” · word for word

No product revenue; reliance on future approvals

“We have not generated any revenue from product sales, and do not expect to do so for several years, if at all.” · word for word

Significant operating losses; need for additional capital

“We have incurred recurring operating losses since inception, including a net loss of $214.4 million for the nine months ended September 30, 2025.” · word for word

Clinical trial risk; regulatory uncertainty

“We may never obtain regulatory approval for any of our product candidates.” · word for word

Clinical and regulatory risk: relutrigine interim analysis in Q4 2025 could fail; vormatrigine POWER1 topline in 1H 2026 could miss endpoints.

“if successful, supports another potential NDA submission for relutrigine in SCN2A/8A DEEs in early 2026” · word for word

Commercialization risk: first commercial launch for a CNS drug; no prior commercial infrastructure; competition from existing ET treatments.

“preparing for our first commercial launch, establishing Praxis as the leader in innovative therapies for CNS disorders.”

Dilution risk: October 2025 public offering increased share count; further capital raises may be needed before profitability.

“Pro forma cash and investments of approximately $956 million, including proceeds from October 2025 public offering” · word for word